Impact of anti-PCSK9 antibody Alirocumab on lipid-lowering on patient motivation to treatment for hypercholesterolemia.

Impact of anti-PCSK9 antibody Alirocumab on lipid-lowering on patient motivation to treatment for hypercholesterolemia. - Impact of Alirocumab on patient motivation to treatment.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029310

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia Diabetes mellitus

Interventions

To administrate Alirocumab to patients who have inadequate management of LDL-C levels on maximum tolerated dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with Type1 or Type2 diabetes mellitus 2)Patients with heterozygous familial hypercholesterolemia or hypercholesterolemia at high-cardiovascular risk,who have inadequate management of LDL-C levels on maximum tolerated dose of statin 3)Patients aged equal or over 20 years

Exclusion criteria

Exclusion criteria: 1)Pregnant 2)Drug allergy to Alirocumab 3)Unsuitable patients for this study by physicians decision

Design outcomes

Primary

Measure	Time frame
Change in patient satisfaction and motivation to treatment from baseline to follow-up as scored using questionnaire.	—

Secondary

Measure	Time frame
glucose(fasting), HbA1c,AST,ALT,gamma-GTP,BUN,Cr,CK,TC,LDL-C,HDL-C,TG,Na,K,Cl,Lp(a),hs-CRP Carotid artery ultrasound,PWV	—

Countries

Japan

Contacts

Public ContactYuji Kawaguchi

Minamiosaka Hospital Department of Internal Medicine

y.kawaguchi@minamiosaka.com06-6685-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026